News from intermune, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 24, 2014, 12:00 ET

Roche and InterMune Reach Definitive Merger Agreement

 Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) today announced they have entered into a definitive merger agreement for...

Aug 06, 2014, 16:01 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Reports Second Quarter 2014 Financial Results and Business Highlights

 InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the second quarter ended June 30, 2014.  The company also...

Jul 28, 2014, 08:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune to Release Second Quarter Financial Results on August 6

 InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its second quarter 2014 financial results at the close of the U.S. markets...

Jul 17, 2014, 12:38 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Receives FDA Breakthough Therapy Designation For Pirfenidone, An Investigational Treatment For IPF

 InterMune, Inc. (Nasdaq: ITMN) today announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S. Food and Drug...

May 27, 2014, 07:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Announces Resubmission Of NDA For Pirfenidone For The Treatment Of Patients With IPF

InterMune, Inc. (Nasdaq: ITMN) today announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S. Food and Drug...

May 20, 2014, 17:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Announces Additional Pirfenidone Data in Idiopathic Pulmonary Fibrosis

 InterMune, Inc. (NASDAQ: ITMN) today announced that results of analyses of pooled data from the ASCEND trial and the two previous Phase 3...

May 18, 2014, 17:02 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

Phase 3 ASCEND Study of Pirfenidone in Idiopathic Pulmonary Fibrosis Presented at American Thoracic Society (ATS) and Published in New England Journal of Medicine

InterMune, Inc. (NASDAQ: ITMN) today reported that results from the Phase 3 ASCEND study evaluating pirfenidone in patients with idiopathic...

May 16, 2014, 08:00 ET

InterMune Announces Expanded Access Program for Pirfenidone to Treat Idiopathic Pulmonary Fibrosis (IPF) in the United States

 InterMune, Inc. (NASDAQ: ITMN) today announced it will provide compassionate use of pirfenidone through a multi-center Expanded Access...

May 12, 2014, 08:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Announces Upcoming Data Presentations at 2014 American Thoracic Society Meeting

 InterMune, Inc. (NASDAQ: ITMN) today announced that several investigational molecules and data from studies of pirfenidone will be presented...

May 01, 2014, 16:01 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Reports First Quarter 2014 Financial Results, Clinical Development and Business Highlights

 InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the first quarter ended March 31, 2014.  The company also...

Apr 23, 2014, 08:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune To Release First Quarter Financial Results On May 1

 InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2014 financial results at the close of the U.S. markets...

Mar 13, 2014, 19:20 ET

InterMune Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock

InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 7,500,000 shares of its common stock at a price to the public of $32.75...

Mar 12, 2014, 16:02 ET

InterMune Announces Proposed Public Offering of Common Stock

 InterMune, Inc. (NASDAQ: ITMN) today announced that it plans to offer, subject to market and other conditions, 7,500,000 shares of its common...

Feb 28, 2014, 07:00 ET
Logo InterMune

InterMune® apoya la primera Carta del Paciente europeo sobre la fibrosis pulmonar idiopática

InterMune® anuncia su apoyo a la primera Carta del Paciente europeo sobre la fibrosis pulmonar idiopática (FPI) Para conmemorar el...

Feb 28, 2014, 01:00 ET
Logo InterMune

InterMune® annonce son soutien à la création de la première Charte européenne des patients atteints de fibrose pulmonaire idiopathique (FPI)

A l'occasion de la Journée internationale des maladies rares, InterMune annonce son soutien au développement d'une Charte...

Feb 25, 2014, 07:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)

 InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with...

Jan 09, 2014, 07:30 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Reports Preliminary Fourth Quarter 2013 Esbriet® (pirfenidone) Revenue and Recent Business Highlights

 InterMune, Inc. (NASDAQ: ITMN) today announced unaudited revenue for the fourth quarter and year ended December 31, 2013.  The company...

Jan 06, 2014, 08:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune to Present at J. P. Morgan Healthcare Conference

 InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at...

Dec 10, 2013, 08:00 ET
InterMune logo.  (PRNewsFoto/InterMune, Inc.)

InterMune Announces Support of The Pulmonary Fibrosis Foundation Care Center Network and Patient Registry Initiative

InterMune (NASDAQ: ITMN) today announced its support of the Pulmonary Fibrosis Foundation, a leading patient advocacy organization dedicated...

Nov 05, 2013, 21:25 ET

InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock

InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 6,500,000 shares of its common stock at a price to the public of $13.00...